DUPIXENT demonstrated
rapid lung
function
improvement, sustained
up to ~3 years

Rapid breathing relief patients can feel in 2 weeks and sustained through 1 year^1,2

Baseline Blood EOS ≥300 cells/μL - QUEST (Secondary Endpoint)

~72%

OF THE TOTAL
IMPROVEMENT
AT WEEK 2

LSM change

from baseline

in FEV₁ (mL)

• 500
• 400
• 300
• 200
• 100
• 0

Weeks

• 0
• 2
• 4
• 8
• 12
• 16
• 20
• 24
• 28
• 32
• 36
• 40
• 44
• 48
• 52

470mL IMPROVEMENT AT WEEK 52
in FEV₁ compared
to baseline
FEV₁
of 1.78 L

DUPIXENT 200 mg + SOC (n=264) Placebo + SOC (n=148)

• At Week 12 in patients with no biomarker requirement: 320 mL improvement from baseline in pre-bronchodilator FEV₁ with
  DUPIXENT 200 mg + SOC (n=631) vs 180 mL with placebo + SOC (n=317) (LSM difference: 140 mL [95% CI: 80, 190 mL]) (QUEST, primary endpoint)¹
• At Week 52 in patients with EOS ≥300 cells/μL: 480 mL improvement from baseline in pre-bronchodilator FEV₁ with DUPIXENT
  300 mg + SOC (n=277) vs 230 mL with placebo + SOC (n=142) (QUEST, secondary endpoint)¹
• In QUEST, a significant difference from placebo + SOC was not observed at 12 weeks in change in pre-bronchodilator FEV₁ in patients with baseline blood EOS ≥150 to <300 cells/μL taking DUPIXENT 300 mg + SOC and in patients with baseline blood EOS <150 cells/μL taking DUPIXENT 200 mg or
  300 mg + SOC¹